Researchers from Nankai University reported on [I], a novel EGFR L858R/T790M/C797S inhibitor designed to overcome the most frequent resistances to non-small-cell lung cancer (NSCLC) treatment.
Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50, an immunoliposome that directs T cells to attack solid tumors and enhances anticancer activity with an immune modulator.
Hemogenyx Pharmaceuticals plc has developed a new and improved version of its bispecific antibody CDX for the treatment of relapsed/refractory acute myeloid leukemia, a subset of acute lymphoblastic leukemia, and potentially for conditioning in bone marrow transplantations.
Scientists from Wuhan University and affiliated organizations have published findings from their investigation into the role of Yes-associated protein (YAP), which is a critical effector of the Hippo pathway, in anaplastic thyroid carcinoma.
Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage response inhibitor, and it, too, is looking to raise a series A to take the program through to the end of phase I.
Latvian Institute of Organic Synthesis has identified selenium compounds acting as estrogen receptor α (ER-α; ESR1) modulators reported to be useful for the treatment of cancer.
Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.
Tumor protein p73 (TP73) has been commonly tagged as a putative tumor suppressor, but it may positively regulate the growth and stemness of cancer stem cells.
A recent article by researchers from Hangzhou Medical College reports data from studies that aimed to investigate the mechanisms behind the antitumor activity of the synthetic retinoid analogue WYC-209.
Plexium Inc. has described the efforts that led to the discovery of PLX-4545, an orally bioavailable molecular glue degrader of IKZF2 for the treatment of cancer that is currently undergoing evaluation in a phase I study in healthy volunteers.
RSS
